Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of CKD-387 vs D635 in Healthy Adults
NCT03849339Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2019
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Cmax of Metformin and AUClast of Metformin. Status: unknown.
02
Drugs
dapagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03849339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03849339.